Written Comment Request- Dupixent and Skyrizi
In accordance with COMAR 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment for the cost review study process on:
Dupixent (dupilumab)
Drug Brand Name: Dupixent
Active Moiety or Active Ingredient: dupilumab
Application Number: BLA761055
NDC 11s in the Cost Review Study Process
AND
Skyrizi (risankizumab)
Drug Brand Name: Skyrizi
Active Moiety or Active Ingredient: risankizumab
Application Number: BLA761105
NDC 11s in the Cost Review Study Process
Patient experience and clinician input regarding these drugs are of particular interest but all comments concerning these drug products are encouraged. Written comments are due by the close of business, Tuesday, September 15, 2026. Please submit written comments to comments.pdab@maryland.gov with the subject line “(Drug Name) Comments.”
Comments should be submitted to comments.pdab@maryland.gov.
Please visit the Board's website for more information about the upcoming and previous board meetings, presentation materials, and to learn more about the PDAB's work.
